Flotetuzumab
Flotetuzumab (pronunciation: floh-teh-TOO-zuh-mab) is a type of monoclonal antibody used in the treatment of acute myeloid leukemia (AML).
Etymology
The name "Flotetuzumab" is derived from the International Nonproprietary Names (INN), where "flo-" refers to the target, "t-" represents the product class, and "-uzumab" is a suffix used for humanized antibodies.
Medical Use
Flotetuzumab is used for the treatment of relapsed or refractory acute myeloid leukemia (AML). It is a bispecific antibody, meaning it targets two different antigens simultaneously. In the case of Flotetuzumab, it targets CD123, a protein overexpressed in AML cells, and CD3, a protein found on T cells. By binding to these two proteins, Flotetuzumab brings the T cells and AML cells into close proximity, which allows the T cells to kill the AML cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow.
- CD123: A protein that is often overexpressed in AML cells.
- CD3: A protein found on T cells.
- Bispecific Antibody: An artificial protein that can simultaneously bind to two different types of antigen.
See Also
External links
- Medical encyclopedia article on Flotetuzumab
- Wikipedia's article - Flotetuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski